These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 33896090)

  • 1. HER2 Splice Site Mutation c.1899-1G>A as the Potential Acquired Resistance to Trastuzumab in a Patient with HER2-Positive Gastric Adenocarcinoma.
    Jiao XD; Liu K; Wu Y; Zhou XC; Qin BD; Ling Y; Liu J; He X; Du H; Xiang J; Zang YS
    Oncologist; 2021 Sep; 26(9):717-721. PubMed ID: 33896090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604).
    Saeki H; Oki E; Kashiwada T; Arigami T; Makiyama A; Iwatsuki M; Narita Y; Satake H; Matsuda Y; Sonoda H; Shimokawa M; Maehara Y;
    Eur J Cancer; 2018 Dec; 105():41-49. PubMed ID: 30391779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High tumor mutation burden in a patient with metastatic gastric cancer sensitive to trastuzumab: a case report.
    Hu CT; Zhou YC; Zu LD; Fu GH; Li Q
    Ann Palliat Med; 2021 May; 10(5):5846-5852. PubMed ID: 32921108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study.
    Meulendijks D; Beerepoot LV; Boot H; de Groot JW; Los M; Boers JE; Vanhoutvin SA; Polee MB; Beeker A; Portielje JE; de Jong RS; Goey SH; Kuiper M; Sikorska K; Beijnen JH; Tesselaar ME; Schellens JH; Cats A
    Invest New Drugs; 2016 Feb; 34(1):119-28. PubMed ID: 26643663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
    Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
    BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Practice Observation of Trastuzumab in Patients with Human Epidermal Growth Receptor 2-Positive Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.
    Al-Batran SE; Moorahrend E; Maintz C; Goetze TO; Hempel D; Thuss-Patience P; Gaillard VE; Hegewisch-Becker S
    Oncologist; 2020 Aug; 25(8):e1181-e1187. PubMed ID: 32311799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of PI3KCA and BRAF mutations in gastric adenocarcinoma: An approach to a personalized targeted therapy for Moroccan HER2 overexpressed patients.
    Joutei HAH; Marchoudi N; Mahfoud W; Sadaoui I; Fechtali T; Benomar H
    Arab J Gastroenterol; 2018 Dec; 19(4):155-158. PubMed ID: 30503528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current status and future perspectives in HER2 positive advanced gastric cancer.
    Roviello G; Catalano M; Iannone LF; Marano L; Brugia M; Rossi G; Aprile G; Antonuzzo L
    Clin Transl Oncol; 2022 Jun; 24(6):981-996. PubMed ID: 35091998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: where do we stand?
    Roviello G; Aprile G; D'Angelo A; Iannone LF; Roviello F; Polom K; Mini E; Catalano M
    Gastric Cancer; 2021 Jul; 24(4):765-779. PubMed ID: 33742317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.
    Thuss-Patience PC; Shah MA; Ohtsu A; Van Cutsem E; Ajani JA; Castro H; Mansoor W; Chung HC; Bodoky G; Shitara K; Phillips GDL; van der Horst T; Harle-Yge ML; Althaus BL; Kang YK
    Lancet Oncol; 2017 May; 18(5):640-653. PubMed ID: 28343975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor Heterogeneity in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer Assessed by CT Texture Analysis: Association with Survival after Trastuzumab Treatment.
    Yoon SH; Kim YH; Lee YJ; Park J; Kim JW; Lee HS; Kim B
    PLoS One; 2016; 11(8):e0161278. PubMed ID: 27517841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PTEN loss is associated with a poor response to trastuzumab in HER2-overexpressing gastroesophageal adenocarcinoma.
    Deguchi Y; Okabe H; Oshima N; Hisamori S; Minamiguchi S; Muto M; Sakai Y
    Gastric Cancer; 2017 May; 20(3):416-427. PubMed ID: 27517839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surgical resection of advanced gastric cancer following trastuzumab/oxaliplatin/capecitabine combination therapy.
    Dong CX; Fu JF; Ye XY; Li XF; Zhong X; Yuan Y
    World J Gastroenterol; 2014 Sep; 20(34):12355-8. PubMed ID: 25232273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trastuzumab in Combination with FOLFIRI in Patients with Advanced HER2-Positive Gastro-Esophageal Adenocarcinoma: A Retrospective Multicenter AGEO Study.
    Zaanan A; Palle J; Soularue E; Leroy F; Louafi S; Tougeron D; Manfredi S; Artru P; Pozet A; Taieb J
    Target Oncol; 2018 Feb; 13(1):107-112. PubMed ID: 29090377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Bang YJ; Van Cutsem E; Feyereislova A; Chung HC; Shen L; Sawaki A; Lordick F; Ohtsu A; Omuro Y; Satoh T; Aprile G; Kulikov E; Hill J; Lehle M; Rüschoff J; Kang YK;
    Lancet; 2010 Aug; 376(9742):687-97. PubMed ID: 20728210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trastuzumab: a review of its use in HER2-positive advanced gastric cancer.
    Sanford M
    Drugs; 2013 Sep; 73(14):1605-15. PubMed ID: 24057416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of trastuzumab and taxane-containing intensified chemotherapy in first-line treatment of HER2-positive advanced gastric cancer.
    Gürbüz M; Akkuş E; Sakin A; Urvay S; Demiray AG; Şahin S; Şakalar T; Erol C; Şendur MAN; Şahin AB; Çubukçu E; Güven DC; Kılıçkap S; Ergün Y; Uncu D; Turhal NS; Üskent N; Yeşil Çınkır H; Demir A; Acar R; Karadurmuş N; Türker S; Altınbaş M; Karaoğlan M; Çay Şenler F
    Tumori; 2021 Oct; 107(5):416-423. PubMed ID: 33167790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment Patterns and Outcomes in Chinese Patients with Gastric Cancer by HER2 Status: A Noninterventional Registry Study (EVIDENCE).
    Qin S; Ji J; Xu RH; Wang W; Tang Y; Bi F; Li J; Wang K; Xu JM; Fan Q; Su W; Shen L
    Oncologist; 2021 Sep; 26(9):e1567-e1580. PubMed ID: 34003545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of HER2 Status Before and After Trastuzumab-based Chemotherapy in Patients With Advanced Gastric Cancer.
    Kijima T; Arigami T; Uenosono Y; Hiraki T; Yanagita S; Matsushita D; Okubo K; Shimonosono M; Ishigami S; Maemura K; Tanimoto A; Natsugoe S
    Anticancer Res; 2020 Jan; 40(1):75-80. PubMed ID: 31892554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multi-institution phase II study of docetaxel and S-1 in combination with trastuzumab for HER2-positive advanced gastric cancer (DASH study).
    Kagawa S; Muraoka A; Kambara T; Nakayama H; Hamano R; Tanaka N; Noma K; Tanakaya K; Kishimoto H; Shigeyasu K; Kuroda S; Kikuchi S; Kuwada K; Nishizaki M; Shirakawa Y; Fujiwara T
    Cancer Chemother Pharmacol; 2018 Feb; 81(2):387-392. PubMed ID: 29290024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.